Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial

Ehab Bakbak, Aishwarya Krishnaraj,Deepak L. Bhatt,Adrian Quan,Brady Park, Asaad I. Bakbak,Basel Bari, Kristin A. Terenzi, Yi Pan, Elizabeth J. Fry,Daniella C. Terenzi,Pankaj Puar, Tayyab S. Khan,Ori D. Rotstein,C. David Mazer,Lawrence A. Leiter,Hwee Teoh,David A. Hess,Subodh Verma

Med(2024)

引用 0|浏览1
暂无评分
摘要
Background REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) showed that icosapent ethyl (IPE) reduced major adverse cardiovascular events by 25%. Since the underlying mechanisms for these benefits are not fully understood, the IPE-PREVENTION CardioLink-14 trial (ClinicalTrials.gov: NCT04562467) sought to determine if IPE regulates vascular regenerative (VR) cell content in people with mild to moderate hypertriglyceridemia. Methods Seventy statin-treated individuals with triglycerides ≥1.50 and <5.6 mmol/L and either atherosclerotic cardiovascular disease or type 2 diabetes with additional cardiovascular risk factors were randomized to IPE (4 g/day) or usual care. VR cells with high aldehyde dehydrogenase activity (ALDHhi) were isolated from blood collected at the baseline and 3-month visits and characterized with lineage-specific cell surface markers. The primary endpoint was the change in frequency of pro-vascular ALDHhiside scatter (SSC)lowCD133+ progenitor cells. Change in frequencies of ALDHhiSSCmid monocyte and ALDHhiSSChi granulocyte precursor subsets, reactive oxygen species production, serum biomarkers, and omega-3 levels were also evaluated. Findings Baseline characteristics, cardiovascular risk factors, and medications were balanced between the groups. Compared to usual care, IPE increased the mean frequency of ALDHhiSSClowCD133+ cells (−1.00% ± 2.45% vs. +7.79% ± 1.70%; p = 0.02), despite decreasing overall ALDHhiSSClow cell frequency. IPE assignment also reduced oxidative stress in ALDHhiSSClow progenitors and increased ALDHhiSSChi granulocyte precursor cell content. Conclusions IPE-PREVENTION CardioLink-14 provides the first translational evidence that IPE can modulate VR cell content and suggests a novel mechanism that may underlie the cardioprotective effects observed with IPE in REDUCE-IT. Funding HLS Therapeutics provided the IPE in kind and had no role in the study design, conduct, analyses, or interpretation.
更多
查看译文
关键词
icosapent ethyl,progenitor cells,cardiovascular disease,vessel repair,granulocytes,omega-3,aldefluor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要